TPST:NASDAQTempest Therapeutics, Inc. Analysis

Tempest Therapeutics is trading at $1.77, barely above its recent support level of $1.64, with the 20‑day SMA (≈$1.91) modestly above the 50‑day SMA (≈$1.89) indicating a slight upward bias that is being eroded by a bearish MACD crossover and a neutral RSI around 44. Volatility is extreme at roughly 97% over the past month and a beta of 1.68 underscores heightened market sensitivity, while decreasing volume signals waning short‑term buying interest. Fundamentally, the company reports zero revenue, negative EBITDA of $26 M and a cash balance of $7.7 M offset by $8.1 M of debt, yielding a negative ROE and a forward PE of –1.46. Recent material news highlights positive interim data from the REDEEM‑1 Phase 1/2a trial of TPST‑2003 in relapsed/refractory multiple myeloma, which could serve as a catalyst if subsequent phases confirm efficacy.
Given the 52‑week low of $1.50 and a reported upside potential of over 500%, the stock appears markedly undervalued relative to its speculative upside, yet the absence of commercial revenue and ongoing cash burn impose substantial execution risk. The lack of dividend, high sector and regulatory risk, and a thin market cap of roughly $26 M suggest caution, but the pipeline progress may justify a long‑term accumulation thesis.